Pharmacyclics LLC
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1991-01-01
- Employees
- 607
- Market Cap
- -
- Website
- http://www.pharmacyclics.com
Clinical Trials
116
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (114 trials with phase data)• Click on a phase to view related trials
Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- First Posted Date
- 2018-12-31
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 59
- Registration Number
- NCT03790332
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
🇺🇸University of California, San Francisco, California, United States
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)
- Conditions
- Mantle-Cell Lymphoma
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 352
- Registration Number
- NCT03112174
- Locations
- 🇺🇸
The University of Arizona Cancer Centre-North Campus, Tucson, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 193
- Registration Number
- NCT02959944
- Locations
- 🇺🇸
Arizona Oncology - Scottsdale - Cancer Transplant Institute Location /ID# 1140-1120, Scottsdale, Arizona, United States
🇺🇸LPCH Stanford /ID# 1140-1128, Palo Alto, California, United States
🇺🇸Ucsf /Id# 1140-0003, San Francisco, California, United States
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 445
- Registration Number
- NCT02947347
- Locations
- 🇺🇸
Southern Cancer Center, Mobile, Alabama, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Sansum Clinic, Santa Barbara, California, United States
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
- Conditions
- LeukemiaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 323
- Registration Number
- NCT02910583
- Locations
- 🇺🇸
City of Hope /ID# 1142-0047, Duarte, California, United States
🇺🇸Moores Cancer Center at UC San Diego /ID# 1142-0241, La Jolla, California, United States
🇺🇸UC Irvine Medical Center - Chao Family Comprehensive Cancer Center /ID# 1142-0008, Orange, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next